Suppr超能文献

可切除的局部晚期食管鳞状细胞癌新辅助免疫治疗联合化疗的病理完全缓解预测:来自综合炎症和营养评分的真实世界证据

Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores.

作者信息

Feng Jifeng, Wang Liang, Yang Xun, Chen Qixun, Cheng Xiangdong

机构信息

Department of Thoracic Oncological Surgery, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.

Zhejiang Provincial Research Center for Upper Gastrointestinal Tract Cancer, Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.

出版信息

J Inflamm Res. 2022 Jul 6;15:3783-3796. doi: 10.2147/JIR.S367964. eCollection 2022.

Abstract

PURPOSE

Neoadjuvant immunotherapy and chemotherapy (nICT) is an emerging hotspot that has been shown to be safe and feasible for locally advanced esophageal squamous cell carcinoma (LA-ESCC). This real-world study aimed to develop and validate a novel predictive model [integrative inflammatory and nutritional score (IINS)] in LA-ESCC patients receiving nICT to predict the pathologic complete response (pCR).

PATIENTS AND METHODS

Patients with LA-ESCC who received nICT followed by surgery from Jun 2019 to Dec 2021 were enrolled and randomly divided into two sets (7:3). Using least absolute shrinkage and selection operator (LASSO) logistic regression analysis, the IINS was constructed in LA-ESCC patients received nICT to predict pCR. A nomogram based on IINS for pCR prediction was generated in the training cohort and verified in the validation cohort.

RESULTS

Of the 285 enrolled LA-ESCC patients received nICT followed by radical resection, 84 (29.5%) patients achieved pCR. A predictive index of IINS based on 8 inflammatory and nutritional indicators was constructed using the LASSO model. According to the cutoff finder, patients were then stratified into two groups (high and low). The pCR rates were significantly higher in high-IINS group than in low-IINS group in both the training cohort (44.7% vs 17.4%, P < 0.001) and validation cohort (50.0% vs 13.3%, P < 0.001). The IINS [odds ratio (OR) = 0.237, 95% confidence interval (CI) = 0.117-0.480, P < 0.001] was an independent significant predictor for pCR in multivariate logistic analyses. The IINS-based nomogram showed an excellent discrimination for pCR prediction (C-indexes = 0.759 and 0.812 for training and validation cohorts, respectively).

CONCLUSION

Pretreatment IINS is an independent predictor for pCR in LA-ESCC patients who are treated with nICT. To our knowledge, the IINS-based nomogram is the first model for pCR prediction and may serve as a simple and potential risk stratification model in LA-ESCC who are treated with nICT.

摘要

目的

新辅助免疫治疗和化疗(nICT)是一个新兴的热点领域,已被证明对局部晚期食管鳞状细胞癌(LA-ESCC)是安全可行的。这项真实世界研究旨在开发并验证一种新的预测模型[综合炎症和营养评分(IINS)],用于预测接受nICT的LA-ESCC患者的病理完全缓解(pCR)。

患者与方法

纳入2019年6月至2021年12月期间接受nICT后行手术治疗的LA-ESCC患者,并随机分为两组(7:3)。使用最小绝对收缩和选择算子(LASSO)逻辑回归分析,在接受nICT的LA-ESCC患者中构建IINS以预测pCR。在训练队列中生成基于IINS的pCR预测列线图,并在验证队列中进行验证。

结果

在285例接受nICT后行根治性切除的LA-ESCC患者中,84例(29.5%)患者达到pCR。使用LASSO模型构建了基于8项炎症和营养指标的IINS预测指数。根据截断值查找器,将患者分为两组(高分组和低分组)。在训练队列(44.7%对17.4%,P<0.001)和验证队列(50.0%对13.3%,P<0.001)中,高IINS组的pCR率均显著高于低IINS组。在多因素逻辑分析中,IINS[比值比(OR)=0.237,95%置信区间(CI)=0.117-0.480,P<0.001]是pCR的独立显著预测因素。基于IINS的列线图对pCR预测具有良好的区分度(训练队列和验证队列的C指数分别为0.759和0.812)。

结论

治疗前IINS是接受nICT治疗的LA-ESCC患者pCR的独立预测因素。据我们所知,基于IINS的列线图是首个用于pCR预测的模型,可能作为接受nICT治疗 的LA-ESCC患者简单且有潜力的风险分层模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8940/9271687/81c2ec69d2ef/JIR-15-3783-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验